88824-78-6
88824-78-6
Chemical Structure
Cilazapril hydrochloride
Synonym(s): Ro 31-2848 hydrochloride
- CAS No.: 88824-78-6
- Formula:C22H32ClN3O5
- Molecular Weight:453.96
InChIKey: QCYBBLWVNJYHEC-YOTVLOEGSA-N
SMILES: OC([C@H]1N2N(CCC[C@@H](C2=O)N[C@H](C(OCC)=O)CCC3=CC=CC=C3)CCC1)=O.Cl
Biological Activity: Cilazapril hydrochloride is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril hydrochloride reduces plasma ACE activity. Cilazapril hydrochloride can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cilazapril hydrochloride | Cilazapril hydrochloride is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril hydrochloride reduces plasma ACE activity. Cilazapril hydrochloride can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cilazapril-d5 trifluoroacetate | Cilazapril-d5 (Ro 31-2848-d5) trifluoroacetate is the deuterium labeled Cilazapril (HY-A0043). Cilazapril is an angiotensin-converting enzyme (ACE) inhibitor used for the study of hypertension and congestive heart failure. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Waterfall JF. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):139S-150S. [Content Brief]
- [2]. Bhutto IA, et al. Effects of cilazapril on the retinal vessels in spontaneously hypertensive rats: corrosion cast and scanning electron microscopic study. Life Sci. 1999;64(3):PL27-39. [Content Brief]
- [3]. Asahi T, et al. Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats. Thyroid. 2001 Nov;11(11):1009-15. [Content Brief]
- [4]. Szucs, T., Cilazapril. A review. Drugs, 1991. 41 Suppl 1: p. 18-24. [Content Brief]
- [5]. Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol, 1987. 9(1): p. 39-44. [Content Brief]
